Showing 1 - 10 of 22
This article discusses the development of Heath Technology Assessment methods and HTA institutions, in regards to meeting the information needs of all levels and fields of health policy-making. On the one hand, HTA needs to expand and develop its methods. Although health products and health care...
Persistent link: https://www.econbiz.de/10008620242
Persistent link: https://www.econbiz.de/10005508826
Persistent link: https://www.econbiz.de/10005509007
Persistent link: https://www.econbiz.de/10005516444
Persistent link: https://www.econbiz.de/10005517095
Persistent link: https://www.econbiz.de/10005520118
In 2011, the EU Directive on Patients’ Rights in Cross Border Healthcare was approved, including a regulation on mutual recognition of prescriptions.
Persistent link: https://www.econbiz.de/10010776763
Funding of diagnostic and therapeutic methods in Germany's statutory health insurance (SHI) follows a dichotomy: in outpatient care, only methods with proven benefit are reimbursed while in inpatient care, all methods may be provided unless they are excluded due to proven harm or lack of...
Persistent link: https://www.econbiz.de/10011048285
Measures of avoidable deaths incorporate the notion that deaths from certain causes should not occur within specified age groups given effective prevention or timely and appropriate access to health care. The present study investigated the impact on specific types of avoidable cancer deaths...
Persistent link: https://www.econbiz.de/10011048312
In the past, free price setting mechanisms in Germany led to high prices of patented pharmaceuticals and to increasing expenditures in the pharmaceutical sector. In order to control patented pharmaceutical prices and to curb increasing pharmaceutical spending, the Act for Restructuring the...
Persistent link: https://www.econbiz.de/10011048324